2021年

by 腫瘍病態学分野
  1. Natsumeda M, Igarashi H, Gabdulkhaev R, Takahashi H, Motohashi K, Ogura R, Watanabe J, Tsukamoto Y, Okamoto K, Kakita A, Nakada T, Fujii Y. Detection of 2-hydroxyglutarate by 3.0-tesla magnetic resonance spectroscopy in glioma with rare IDH mutations: making sense of “false-positive” cases. Diagnostics (Basel), 11(11):2129, 2021.
  2. Aoki T, Kagawa N, Sugiyama K, Wakabayashi T, Arakawa Y, Yamaguchi S, Tanaka S, Ishikawa E, Muragaki Y, Nagane M, Nakada M, Suehiro S, Hata N, Kuroda J, Narita Y, Sonoda Y, Iwadate Y, Natsumeda M, Nakazato Y, Minami H, Hirata Y, Hagihara S, Nishikawa R. Efficacy and safety of nivolumab in Japanese patients with first recurrence: an open-label, non-comparative study. Int J Clin Oncol, 26(12):2205-15, 2021. 
  3. Natsumeda M, Chang M, Gabdulkhaev R, Takahashi H, Tsukamoto Y, Kanemaru Y, Okada M, Oishi M, Okamoto K, Rodriguez FJ, Kakita A, Fujii Y, Schreck KC. Predicting BRAF V600E mutation in glioblastoma- utility of radiographic features. Brain Tumor Pathol, 38(3): 228-233, 2021.
  4. Kanamori M, Takami H, Suzuki T, Tominaga T, Kurihara J, Tanaka S, Hatazaki S, Nagane M, Matsuda M, Yoshino A, Natsumeda M, Yamaoka M, Kagawa N, Akiyama Y, Fukai J, Negoto T, Shibahara I, Tanaka K, Inoue A, Mase M, Tomita T, Kuga D, Kijima N, Fukami T, Nakahara Y, Natsume A, Yoshimoto K, Keino D, Tokuyama T, Asano K, Ujifuku K, Abe H, Nakada M, Matsuda K, Arakawa Y, Ikeda N, Narita Y, Shinojima N, Kambe A, Nonaka M, Izumoto S, Kawanishi Y, Kanaya K, Nomura S, Nakajima K, Yamamoto S, Terashima K, Ichimura K, Nishikawa R. Necessity for craniospinal irradiation of germinoma with positive cytology but without spinal lesion on MR imaging – a controversy. Neurooncol Adv, 3(1): vdab086, 2021.
  5. Natsumeda M, Kanemaru Y, Kawaguchi Y, Umezu H, Kakita A, Fujii Y. Less-invasive diagnosis of disseminated epithelioid glioblastoma harboring BRAF V600E mutation by cerebrospinal fluid analysis -a case report. Clin Case Rep, 9(7):e04551, 2021.
  6. Natsumeda M, On J, Watanabe J, Tsukamoto Y, Okada M, Fujii Y, Adachi J, Nishikawa R. The present and future of less-invasive liquid biopsy for the diagnosis of gliomas and brain tumors. No Shinkei Geka, 49(3): 527-534, 2021.(和)
  7. Okada M, Kawasaki A, Kaneko A, Kaneko N, Natsumeda M, Oishi M, Fujii Y, Igarashi M. Phosphorylated T172 in GAP-43: A novel molecular marker of axonal growth and regeneration in primate neurons identified by phosphoproteomics. Cytometry Res, 31(1): 1-7, 2021.
  8. On J, Natsumeda M, Watanabe J, Saito S, Kanemaru Y, Abe H, Tsukamoto Y, Okada M, Oishi M, Yoshimura J, Kakita A, Fujii Y. Low detection rate of H3K27M mutations in cerebrospinal fluid taken by lumbar puncture in newly diagnosed diffuse midline gliomas. Diagnostics, 11(4), 2021. 
  9. Igarashi H, Takeda M, Natsumeda M, Fujii Y. Proton magnetic resonance spectroscopy (1H-MRS). No Shinkei Geka, 49(2):438-444, 2021.(和)
  10. Okamoto K, Natsumeda M, Oishi M, Fujii Y. Dysplastic Cerebellar Gangliocytoma (Lhermitte-Duclos Disease). No Shinkei Geka, 49(2):395-399, 2021. (和)
  11. Okamoto K, Natsumeda M, Oishi M, Fujii Y. Melanocytic tumors. No Shinkei Geka, 49(2):389-394, 2021. (和)
  12. Okamoto K, Natsumeda M, Oishi M, Fujii Y. Multinodular and vacuolating neuronal tumor of the cerebrum (MVNT). No Shinkei Geka, 49(2):383-387, 2021. (和)
  13. Miyahara H, Natsumeda M, Kanemura Y, Yamasaki K, Riku Y, Akagi A, Oohashi W, Shofuda T, Yoshioka E, Sato Y, Taga T, Naruke Y, Ando R, Hasegawa D, Yoshida M, Sakaida T, Okada N, Watanabe H, Ozeki M, Arakawa Y, Yoshimura J, Fujii Y, Suenobu S, Ihara K, Hara J, Kakita A, Yoshida M, Iwasaki Y. Topoisomerase IIβ immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Children’s Cancer Group. Brain Tumor Pathol, 49(3):527-534, 2021.
  14. Klionsky D, …, Natsumeda M, 2922 other authors. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy, 17(1):1-382, 2021.
  15. Ogura R, Oishi M, Hiraishi T, Takahashi H, Shibuya K, Suzuki T, Natsumeda M, Okamoto K, Fujii Y. Four-dimensional multifusion imaging for assessment of meningioma hemodynamics. Interdiscip Neurosurg: Adv Techniques and Case Management, 24(1):101118, 2021.
  16. Natsumeda M, Miyahara H, Yoshimura J, Nakata S, Nozawa T, Ito J, Kanemaru Y, Watanabe J, Tsukamoto Y, Okada M, Oishi M, Hirato J, Wataya T, Ahsan S, Tateishi K, Yamamoto T, Rodriguez FJ, Takahashi H, Hovestadt V, Suva ML, Taylor MD, Eberhart CG, Fujii Y, Kakita A. GLI3 is associated with neuronal differentiation in SHH-activated and WNT-activated medulloblastoma. J Neuropathol Exp Neurol, 80(2):129-136, 2021.
  17. Kanamori M, Takami H, Yamaguchi S, Sasayama T, Yoshimoto K, Tominaga T, Inoue A, Ikeda N, Kambe A, Kumabe T, Matsuda M, Tanaka S, Natsumeda M, Matsuda KI, Nonaka M, Jun K, Yamaoka M, Kagawa N, Shinojima N, Negoto T, Nakahara Y, Arakawa Y, Hatazaki S, Shimizu H, Yoshino A, Abe H, Akimoto J, Kawanishi Y, Suzuki T, Natsume A, Nagane M, Akiyama Y, Keino D, Fukami T, Tomita T, Kanaya K, Tokuyama T, Izumoto S, Nakada M, Kuga D, Yamamoto S, Anei R, Uzuka T, Fukai J, Kijima N, Terashima K, Ichimura K, Nishikawa R. So-called “bifocal tumors” with diabetes insipidus and negative tumor markers: Are they all germinoma? Neuro Oncol, 23(2):295-303, 2021.